Olaparib (AZD2281)

Name: Olaparib (AZD2281)
Brand: Selleck Chemicals
SKU: S1060
Rating: 5 (586 reviews)

For research use only.

Catalog No.S1060 Synonyms: Ku-0059436

586 publications

CAS No. 763113-22-0

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1. Olaparib induces significant autophagy that is associated with mitophagy in cells with BRCA mutations.

Selleck's Olaparib (AZD2281) has been cited by 586 publications

Cancer Cell, 2020, 15 pii: S1535-6108(20)30164-1

PubMed: 32359397 ( click the link to review the publication )

Cancer Cell, 2020, 37(2):157-167

PubMed: 32004442 ( click the link to review the publication )

Cancer Cell, 2020, 37(3):340-353

PubMed: 32109375 ( click the link to review the publication )

Cancer Discov, 2019, 9(6):722-737

PubMed: 31015319 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cancer Cell, 2019, 35(3):519-533

PubMed: 30889383 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Nature, 2018, 555(7696):387-391

PubMed: 29513652 ( click the link to review the publication )

Nature, 2018, 560(7716):112-116

PubMed: 30022158 ( click the link to review the publication )

Nature, 2018, 560(7716):117-121

PubMed: 30022168 ( click the link to review the publication )

Nat Biotechnol, 2018, 36(1):95-102

PubMed: 29176614 ( click the link to review the publication )

Cell, 2018, 173(4):972-988

PubMed: 29656893 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Genet, 2018, 50(8):1086-1092

PubMed: 30013182 ( click the link to review the publication )

Cancer Discov, 2018, 8(1):74-93

PubMed: 28923912 ( click the link to review the publication )

Cancer Discov, 2018, 8(8):988-1005

PubMed: 29880585 ( click the link to review the publication )

Cancer Cell, 2018, 33(2):202-216

PubMed: 29358035 ( click the link to review the publication )

Cancer Cell, 2018, 33(3):401-416

PubMed: 29533782 ( click the link to review the publication )

Cell Metab, 2018, 1;27(5):1067-1080.e5

PubMed: 29685734 ( click the link to review the publication )

Nature, 2017, 549(7673):548-552

PubMed: 28959974 ( click the link to review the publication )

Nature, 2017, 550(7676):360-365

PubMed: 28976962 ( click the link to review the publication )

Cell, 2017, 170(6):1079-1095.e20

PubMed: 28823558 ( click the link to review the publication )

Cell, 2017, S0092-8674(17)31437-X

PubMed: 29290468 ( click the link to review the publication )
Nat Med, 2016, 22(2):194-201

PubMed: 26779812 ( click the link to review the publication )

Nature, 2015, 528(7582):422-6

PubMed: 26649820 ( click the link to review the publication )

Cell, 2014, 8;157(4):882-896.

PubMed: 24813611 ( click the link to review the publication )

Cell Metab, 2014, 19(6):1034-41

PubMed: 24814482 ( click the link to review the publication )

Science, 2013, 339(6120):700-4

PubMed: 23306437 ( click the link to review the publication )

Nat Methods , 2013, 10(10):981-4

PubMed: 23955771 ( click the link to review the publication )

Cancer Discov, 2012, 2(11):1036-47

PubMed: 22915752 ( click the link to review the publication )

Cell, 2011, 13;145(4):529-42.

PubMed: 21565612 ( click the link to review the publication )

Mol Med Rep, 2021, 23(1)40

PubMed: 33179075 ( click the link to review the publication )

Nat Cell Biol, 2020, 22(1):87-96

PubMed: 31915374 ( click the link to review the publication )

Nat Struct Mol Biol, 2020, 10.1038/s41594-020-0512-7

PubMed: 33046907 ( click the link to review the publication )

Nat Commun, 2020, 11(1):5775

PubMed: 33188175 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3018

PubMed: 32541668 ( click the link to review the publication )

Nat Commun, 2020, 5;11(1):2834

PubMed: 32503981 ( click the link to review the publication )

Nat Commun, 2020, 1;11(1):2147

PubMed: 32358495 ( click the link to review the publication )

Nat Commun, 2020, 26;11(1):2641

PubMed: 32457376 ( click the link to review the publication )

Nat Commun, 2020, 14;11(1):1819

PubMed: 32286328 ( click the link to review the publication )

Nat Commun, 2020, 22;11(1):2573

PubMed: 32444794 ( click the link to review the publication )

Nat Commun, 2020, 20;11(1):1884

PubMed: 32313004 ( click the link to review the publication )

Nat Commun, 2020, 1;11(1):2174

PubMed: 32358582 ( click the link to review the publication )

Sci Adv, 2020, 22;6(17):eaaz3221

PubMed: 32494639 ( click the link to review the publication )

Nucleic Acids Res, 2020, 48(17):9710-9723

PubMed: 32890395 ( click the link to review the publication )

Nucleic Acids Res, 2020, 15;gkaa508

PubMed: 32542389 ( click the link to review the publication )

Nucleic Acids Res, 2020, 10.1093/nar/gkaa022

PubMed: 31965183 ( click the link to review the publication )
Nucleic Acids Res, 2020, 10.1093/nar/gkaa038

PubMed: 31980815 ( click the link to review the publication )

Nucleic Acids Res, 2020, gkaa782

PubMed: 33010172 ( click the link to review the publication )

Nucleic Acids Res, 2020, 16 pii: gkaa255

PubMed: 32297953 ( click the link to review the publication )

EMBO J, 2020, e103420

PubMed: 32935380 ( click the link to review the publication )

J Thorac Oncol, 2020, 10.1016/j.jtho.2020.01.012

PubMed: 32004714 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-19-2000

PubMed: 31900275 ( click the link to review the publication )

Dev Cell, 2020, 20;53(2):240-252

PubMed: 32197067 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

J Cell Biol, 2020, 219(8):e202002175

PubMed: 32597933 ( click the link to review the publication )

Theranostics, 2020, 10(15):6959-6976

PubMed: 32550915 ( click the link to review the publication )

Cancer Res, 2020, 10.1158/0008-5472.CAN-19-2069

PubMed: 32019870 ( click the link to review the publication )

Cancer Res, 2020, 80(18):3841-3854

PubMed: 32690724 ( click the link to review the publication )

Cancer Res, 2020, 80(20):4514-4526

PubMed: 32859605 ( click the link to review the publication )

Cancer Res, 2020, 10.1158/0008-5472.CAN-19-2739

PubMed: 32193285 ( click the link to review the publication )

Cell Rep, 2020, 32(12):108184

PubMed: 32966782 ( click the link to review the publication )

Cell Rep, 2020, 33(1):108221

PubMed: 33027668 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Cell Rep, 2020, 33(5):108347

PubMed: 33147465 ( click the link to review the publication )

Cell Rep, 2020, 33(2):108240

PubMed: 33053351 ( click the link to review the publication )

Cell Rep, 2020, 31(10):107745

PubMed: 32521270 ( click the link to review the publication )

Haematologica, 2020, 10.3324/haematol.2019.240713

PubMed: 32079692 ( click the link to review the publication )

J Hematol Oncol, 2020, 13(1):9

PubMed: 32005272 ( click the link to review the publication )

Oncogene, 2020, 39(14):2905-2920

PubMed: 32029902 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-1175-x

PubMed: 32001817 ( click the link to review the publication )
EBioMedicine, 2020, 59:102971

PubMed: 32846370 ( click the link to review the publication )

Cancer Lett, 2020, 469:78-88

PubMed: 31629931 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 39(1):3

PubMed: 31898520 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3127

PubMed: 33114555 ( click the link to review the publication )

Cancers (Basel), 2020, 12(10)E2809

PubMed: 33003585 ( click the link to review the publication )

Cancers (Basel), 2020, 7;12(5) pii: E1180

PubMed: 32392755 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32093123 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32033118 ( click the link to review the publication )

Cell Death Dis, 2020, 11(10):898

PubMed: 33093458 ( click the link to review the publication )

Cell Death Dis, 2020, 11(10):851

PubMed: 33051436 ( click the link to review the publication )

BMC Biol, 2020, 18(1):143

PubMed: 33059680 ( click the link to review the publication )

BMC Biol, 2020, 30;18(1):36

PubMed: 32228693 ( click the link to review the publication )

J Clin Med, 2020, 30;9(4)

PubMed: 32235451 ( click the link to review the publication )

Cells, 2020, 9(9)E2110

PubMed: 32948057 ( click the link to review the publication )

Cells, 2020, 8;9(4)

PubMed: 32276472 ( click the link to review the publication )

Cells, 2020, 7;9(2)

PubMed: 32046043 ( click the link to review the publication )

Cancer Discov, 2020, CD-20-0226

PubMed: 32606138 ( click the link to review the publication )

Mol Cancer Ther, 2020, 10.1158/1535-7163.MCT-19-0926

PubMed: 32127465 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):552-563

PubMed: 31619462 ( click the link to review the publication )

Mol Cell Proteomics, 2020, mcp.RA120.002290

PubMed: 32958691 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(8):2649-2676

PubMed: 32905466 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(10):3458-3474

PubMed: 33163283 ( click the link to review the publication )

Gynecol Oncol, 2020, 157(1):222-233

PubMed: 31987601 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0507

PubMed: 32229503 ( click the link to review the publication )
J Cell Mol Med, 2020, 10.1111/jcmm.14980

PubMed: 32032474 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(4)

PubMed: 32053991 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Sci Rep, 2020, 10(1):15086

PubMed: 32934320 ( click the link to review the publication )

Sci Rep, 2020, 17;10(1):2585

PubMed: 32066817 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Cell Cycle, 2020, 1-19

PubMed: 33044911 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(7):1659-1670

PubMed: 32279088 ( click the link to review the publication )

Oncol Rep, 2020, 43(5):1397-1412

PubMed: 32323799 ( click the link to review the publication )

Eur J Pharmacol, 2020, 15;877:173091

PubMed: 32234526 ( click the link to review the publication )

Biochemistry, 2020, 10.1021/acs.biochem.0c00256

PubMed: 32357296 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2020, 85(2):273-284

PubMed: 31907647 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2020, 28

PubMed: 32468080 ( click the link to review the publication )

PLoS One, 2020, 15(9):e0238238

PubMed: 32881880 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 522(4):945-951

PubMed: 31806370 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

J Radiat Res, 2020, 23;61(2):177-186

PubMed: 31976528 ( click the link to review the publication )

J Radiat Res, 2020, 22;61(3):352-367

PubMed: 32329510 ( click the link to review the publication )

Int J Radiat Biol, 2020, 10.1080/09553002.2020.1711461

PubMed: 31914341 ( click the link to review the publication )

FEBS Open Bio, 2020, 10(10):2055-2071

PubMed: 33017104 ( click the link to review the publication )

Genes Cells, 2020, 10.1111/gtc.12808

PubMed: 32939879 ( click the link to review the publication )

J Proteome Res, 2020, 10.1021/acs.jproteome.0c00261

PubMed: 32529831 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(6):1900-1918

PubMed: 32642299 ( click the link to review the publication )

Mol Cells, 2020, 43(7):632-644

PubMed: 32732457 ( click the link to review the publication )
Nat Biomed Eng, 2020, 4(8):835-844

PubMed: 32541917 ( click the link to review the publication )

Clin Cancer Res, 2020, 10.1158/1078-0432.CCR-20-0638

PubMed: 32571788 ( click the link to review the publication )

Oncol Lett, 2020, 19(4):2629-2638

PubMed: 32218813 ( click the link to review the publication )

FASEB J, 2020, 10.1096/fj.202000044RR

PubMed: 32816354 ( click the link to review the publication )

Sci Rep, 2020, 10(1):11574

PubMed: 32665693 ( click the link to review the publication )

Cancer Res, 2020, 10.1158

PubMed: 32127357 ( click the link to review the publication )

Neoplasia, 2020, 22(9):365-375

PubMed: 32629177 ( click the link to review the publication )

Cells, 2020, 9(7):1593

PubMed: 32630281 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(2):648-661

PubMed: 32195033 ( click the link to review the publication )

RNA, 2020, rna.74625.120

PubMed: 32759388 ( click the link to review the publication )

Cancers (Basel), 2020, 12(6):1503

PubMed: 32526907 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2020, S0304-4165(20)30271-3

PubMed: 33035602 ( click the link to review the publication )

Cytometry A, 2020, 10.1002/cyto.a.23960

PubMed: 31943748 ( click the link to review the publication )

Cell Mol Life Sci, 2020, 10.1007/s00018-020-03618-4

PubMed: 32789690 ( click the link to review the publication )

NAR Cancer, 2020, 2(2):zcaa006

PubMed: 32743550 ( click the link to review the publication )

Transl Oncol, 2020, 13(11):100834

PubMed: 32688248 ( click the link to review the publication )

Cell Rep, 2020, 32(2):107884

PubMed: 32668240 ( click the link to review the publication )

Sci Signal, 2020, 13(645):eaba8091

PubMed: 32817374 ( click the link to review the publication )

Eur J Clin Microbiol Infect Dis, 2020, 1-9

PubMed: 32865668 ( click the link to review the publication )

Biol Blood Marrow Transplant, 2020, 10.1016

PubMed: 32194286 ( click the link to review the publication )

Cell Rep, 2020, 32(5):107985

PubMed: 32755579 ( click the link to review the publication )

Theranostics, 2020, 10(7):3351-3365

PubMed: 32194873 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(3):311-318

PubMed: 30804502 ( click the link to review the publication )

Sci Transl Med, 2019, 11(492)

PubMed: 31092693 ( click the link to review the publication )
Cell Res, 2019, 29(3):233-247

PubMed: 30728452 ( click the link to review the publication )

Nat Microbiol, 2019, 4(11):1872-1884

PubMed: 30988430 ( click the link to review the publication )

Mol Cell, 2019, 10.1016/j.molcel.2019.10.026

PubMed: 31759821 ( click the link to review the publication )

Mol Cell, 2019, 73(4):845-856

PubMed: 30712989 ( click the link to review the publication )

Mol Cell, 2019, 76(3):473-484

PubMed: 31494034 ( click the link to review the publication )

Mol Cell, 2019, 10.1016/j.molcel.2019.09.024

PubMed: 31653568 ( click the link to review the publication )

Mol Cell, 2019, 73(5):885-899

PubMed: 30686591 ( click the link to review the publication )

Mol Cell, 2019, 75(6):1286-1298

PubMed: 31473101 ( click the link to review the publication )

Mol Cell, 2019, 73(2):224-237

PubMed: 30554948 ( click the link to review the publication )

Mol Cell, 2019, 10.1016/j.molcel.2019.10.008

PubMed: 31676232 ( click the link to review the publication )

Mol Cell, 2019, 73(6):1267-1281

PubMed: 30704900 ( click the link to review the publication )

Mol Cell, 2019, 73(4):670-683.e12

PubMed: 30639241 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1307

PubMed: 30898999 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2556

PubMed: 31186408 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4632

PubMed: 31604914 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4363

PubMed: 31554794 ( click the link to review the publication )

J Clin Invest, 2019, 129(3):1211-1228

PubMed: 30589644 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5367

PubMed: 31772167 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5654

PubMed: 31827085 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5296

PubMed: 31757951 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2849

PubMed: 31253762 ( click the link to review the publication )

Nat Commun, 2019, 10(1):241

PubMed: 30651562 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3925

PubMed: 31477700 ( click the link to review the publication )

Nat Commun, 2019, 10(1):65

PubMed: 30622262 ( click the link to review the publication )
Nat Commun, 2019, 10(1):5661

PubMed: 31827092 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5501

PubMed: 31796734 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(11):5634-5647

PubMed: 31006810 ( click the link to review the publication )

Nucleic Acids Res, 2019, 10.1093/nar/gkz820

PubMed: 31566235 ( click the link to review the publication )

Nucleic Acids Res, 2019, 19;47(16):8502-8520

PubMed: 31616951 ( click the link to review the publication )

EMBO J, 2019, 15;38(16):e101284

PubMed: 31294866 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(20):6127-6140

PubMed: 31409614 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(20):6206-6216

PubMed: 31409613 ( click the link to review the publication )

EMBO Mol Med, 2019, 11(7):e9982

PubMed: 31273933 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-2549

PubMed: 31852834 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31439587 ( click the link to review the publication )

Genes Dev, 2019, 33(5-6):333-347

PubMed: 30796017 ( click the link to review the publication )

Genes Dev, 2019, 33(19-20):1397-1415

PubMed: 31467087 ( click the link to review the publication )

Cancer Res, 2019, 79(17):4491-4502

PubMed: 31273064 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-1673

PubMed: 30733193 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-2409

PubMed: 31831554 ( click the link to review the publication )

EMBO Rep, 2019, 20(5)

PubMed: 30940648 ( click the link to review the publication )

J Immunother Cancer, 2019,

PubMed: 31477176 ( click the link to review the publication )

Cancer Res, 2019, 79(8):2031-2041

PubMed: 30824588 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32670

PubMed: 31495919 ( click the link to review the publication )

Int J Cancer, 2019, 144(7):1685-1696

PubMed: 30478958 ( click the link to review the publication )

Int J Cancer, 2019, 144(5):1092-1103

PubMed: 30152517 ( click the link to review the publication )

Oncogene, 2019, 38(2):180-193

PubMed: 30093630 ( click the link to review the publication )
J Med Chem, 2019, 62(11):5330-5357

PubMed: 31042381 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):90

PubMed: 30786932 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):463

PubMed: 31718704 ( click the link to review the publication )

Cancers (Basel), 2019,

PubMed: 31671803 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31627329 ( click the link to review the publication )

Cancers (Basel), 2019, 12(1)

PubMed: 31877762 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12841

PubMed: 31663663 ( click the link to review the publication )

Clin Epigenetics, 2019, 11(1):165

PubMed: 31775874 ( click the link to review the publication )

Cell Death Dis, 2019, 10(4):281

PubMed: 30911007 ( click the link to review the publication )

Br J Cancer, 2019, 121(7):600-610

PubMed: 31481733 ( click the link to review the publication )

FASEB J, 2019, 33(6):6778-6788

PubMed: 30807703 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.10.013

PubMed: 31735695 ( click the link to review the publication )

Stem Cells, 2019, 37(1):42-53

PubMed: 30353615 ( click the link to review the publication )

PLoS Genet, 2019, 15(10):e1008355

PubMed: 31584931 ( click the link to review the publication )

PLoS Genet, 2019, 15(8):e1008319

PubMed: 31381562 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163

PubMed: 31534014 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-17-0256

PubMed: 31575654 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(8):1439-1450

PubMed: 31142662 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0474

PubMed: 31597711 ( click the link to review the publication )

Transl Res, 2019, 10.1016/j.trsl.2019.10.003

PubMed: 31707040 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(11):2442-2455

PubMed: 31815045 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(3):608-618

PubMed: 30949414 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(2):431-445

PubMed: 30401718 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(1):42-53

PubMed: 30201826 ( click the link to review the publication )
Lung Cancer, 2019, 135:56-65

PubMed: 31447003 ( click the link to review the publication )

J Immunol, 2019, 202(5):1406-1416

PubMed: 30674576 ( click the link to review the publication )

Lung Cancer, 2019, 135:56-65

PubMed: 31447003 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(10):1985-1998

PubMed: 31300540 ( click the link to review the publication )

Front Oncol, 2019, 9:1406

PubMed: 31921663 ( click the link to review the publication )

Cancer Sci, 2019, 110(3):1064-1075

PubMed: 30663191 ( click the link to review the publication )

Biochem Pharmacol, 2019, 10.1016/j.bcp.2019.06.022

PubMed: 31251940 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31554189 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(23)

PubMed: 31795418 ( click the link to review the publication )

Sci Rep, 2019, 9(1):11153

PubMed: 31371750 ( click the link to review the publication )

J Biol Chem, 2019, 294(33):12459-12471

PubMed: 31248990 ( click the link to review the publication )

J Biol Chem, 2019, 294(2):397-404

PubMed: 30478172 ( click the link to review the publication )

Mol Carcinog, 2019, 58(10):1770-1782

PubMed: 31219654 ( click the link to review the publication )

Breast Cancer Res Treat, 2019, 176(1):109-117

PubMed: 30989461 ( click the link to review the publication )

Mediators Inflamm, 2019, 2019:1656484

PubMed: 31178661 ( click the link to review the publication )

Invest New Drugs, 2019, 10.1007/s10637-018-00717-9

PubMed: 30612311 ( click the link to review the publication )

Virology, 2019, 537:254-262

PubMed: 31539774 ( click the link to review the publication )

Prostate, 2019, 79(4):390-402

PubMed: 30520109 ( click the link to review the publication )

Cell Cycle, 2019, 1-14

PubMed: 31238782 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):829

PubMed: 31438892 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2019, 10.1007/s00432-019-03097-6

PubMed: 31786739 ( click the link to review the publication )

Cancer Med, 2019, 10.1002/cam4.2528

PubMed: 31512408 ( click the link to review the publication )

Transl Oncol, 2019, 12(7):871-878

PubMed: 31075528 ( click the link to review the publication )

J Gynecol Oncol, 2019, 30(2):e26

PubMed: 30740957 ( click the link to review the publication )
PLoS One, 2019, 14(10):e0223725

PubMed: 31596905 ( click the link to review the publication )

PLoS One, 2019, 14(11):e0221288

PubMed: 31721781 ( click the link to review the publication )

PLoS One, 2019, 14(8):e0213130

PubMed: 31408463 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 508(2):620-625

PubMed: 30522863 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 10.1016/j.bbrc.2019.11.050

PubMed: 31753490 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 510(4):501-507

PubMed: 30737031 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(4):1098-1101

PubMed: 30277116 ( click the link to review the publication )

Mol Cell Biochem, 2019, 457(1-2):41-49

PubMed: 30993494 ( click the link to review the publication )

Mol Med Rep, 2019, 20(4):3609-3616

PubMed: 31485633 ( click the link to review the publication )

Mol Med Rep, 2019, 19(1):75-84

PubMed: 30431088 ( click the link to review the publication )

Am J Vet Res, 2019, 80(7):663-669

PubMed: 31246122 ( click the link to review the publication )

Nanomedicine (Lond), 2019, 14(17):2315-2338

PubMed: 31432749 ( click the link to review the publication )

Oncotarget, 2019, 10(28):2722-2737

PubMed: 31105872 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(20):10662-10677

PubMed: 31586400 ( click the link to review the publication )

Commun Biol, 2019, 2:335

PubMed: 31508509 ( click the link to review the publication )

NPJ Breast Cancer, 2019, 5:14

PubMed: 30993195 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(17):9132-9143

PubMed: 31329989 ( click the link to review the publication )

Cancer Immunol Res, 2019,

PubMed: 30401677 ( click the link to review the publication )

Oncol Rep, 2019, 41(6):3555-3564

PubMed: 31002368 ( click the link to review the publication )

Nat Cell Biol, 2018, 20(2):162-174

PubMed: 29335528 ( click the link to review the publication )

Mol Cell, 2018, 71(1):11-24

PubMed: 29937341 ( click the link to review the publication )

Mol Cell, 2018, 72(4):636-649

PubMed: 30293785 ( click the link to review the publication )

Mol Cell, 2018, 71(6):897-910

PubMed: 30122534 ( click the link to review the publication )

Mol Cell, 2018, 72(1):127-139

PubMed: 30244837 ( click the link to review the publication )
Nat Chem Biol, 2018, 14(9):837-840

PubMed: 30013063 ( click the link to review the publication )

J Clin Invest, 2018, 128(7):2951-2965

PubMed: 29649003 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2678

PubMed: 29992957 ( click the link to review the publication )

J Clin Invest, 2018, 128(10):4525-4542

PubMed: 30222135 ( click the link to review the publication )

Nat Commun, 2018, 9(1):697

PubMed: 29449575 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3982

PubMed: 30266942 ( click the link to review the publication )

Nat Commun, 2018, 9(1):1849

PubMed: 29748565 ( click the link to review the publication )

Nat Commun, 2018, 9(1):176

PubMed: 29330466 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2016

PubMed: 29789535 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

Nat Commun, 2018, 9(1):144

PubMed: 29321523 ( click the link to review the publication )

EMBO Rep, 2018, 19(10)e44445

PubMed: 30177554 ( click the link to review the publication )

EMBO Rep, 2018, 19(10):e46783

PubMed: 30291165 ( click the link to review the publication )

J Immunother Cancer, 2018, 6(1):133

PubMed: 30486888 ( click the link to review the publication )

Cancer Res, 2018, 78(17):5060-5071

PubMed: 29976574 ( click the link to review the publication )

Cell Rep, 2018, 24(9):2493-2505.e4

PubMed: 30157440 ( click the link to review the publication )

Cell Rep, 2018, 24(13):3393-3403

PubMed: 30257201 ( click the link to review the publication )

Cell Rep, 2018, 25(8):2061-2069

PubMed: 30463005 ( click the link to review the publication )

Cell Rep, 2018, 23(11):3127-3136

PubMed: 29898385 ( click the link to review the publication )

Cell Rep, 2018, 24(10):2629-2642

PubMed: 30184498 ( click the link to review the publication )

Cell Rep, 2018, 24(13):3393-3403.e5

PubMed: 30257201 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.37818

PubMed: 30088474 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.38771

PubMed: 29985131 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.29747

PubMed: 29313488 ( click the link to review the publication )
Cancer Lett, 2018, 423:60-70

PubMed: 29526801 ( click the link to review the publication )

J Exp Clin Cancer Res, 2018, 37(1):129

PubMed: 29954437 ( click the link to review the publication )

Cancers (Basel), 2018, 10(5)

PubMed: 29783721 ( click the link to review the publication )

PLoS Pathog, 2018, 14(11):e1007394

PubMed: 30395643 ( click the link to review the publication )

Cell Death Dis, 2018,

PubMed: 29988031 ( click the link to review the publication )

Br J Cancer, 2018, 119(11):1392-1400

PubMed: 30425352 ( click the link to review the publication )

Arch Toxicol, 2018, 92(2):759-775

PubMed: 28975372 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(6):1167-1176

PubMed: 29626126 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2206-2216

PubMed: 29970481 ( click the link to review the publication )

Mol Oncol, 2018, 12(4):561-576

PubMed: 29465803 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):428-438

PubMed: 29222170 ( click the link to review the publication )

Dis Model Mech, 2018,

PubMed: 29666142 ( click the link to review the publication )

Int J Nanomedicine, 2018, 13:8063-8074

PubMed: 30555227 ( click the link to review the publication )

Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )

Biochem Pharmacol, 2018, 150:24-34

PubMed: 29355504 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(9):1837-1846

PubMed: 30323975 ( click the link to review the publication )

Biomed Pharmacother, 2018, 101:719-728

PubMed: 29524880 ( click the link to review the publication )

J Pharmacol Exp Ther, 2018, 365(1):96-106

PubMed: 29420256 ( click the link to review the publication )

J Pharmacol Exp Ther, 2018, 365(1):117-126

PubMed: 29339456 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(9):797-808

PubMed: 29923797 ( click the link to review the publication )

Cancer Biol Ther, 2018, 19(9):797-808

PubMed: 29923797 ( click the link to review the publication )

Cancer Med, 2018, 7(4):1285-1296

PubMed: 29479816 ( click the link to review the publication )

Oncol Rep, 2018, 39(5):2261-2269

PubMed: 29512738 ( click the link to review the publication )

Oncol Rep, 2018, 40(1):479-487

PubMed: 29767248 ( click the link to review the publication )
PLoS One, 2018, 13(3):e0194611

PubMed: 29590171 ( click the link to review the publication )

PLoS One, 2018, 13(11):e0207399

PubMed: 30444904 ( click the link to review the publication )

PLoS One, 2018, 13(1):e0190717

PubMed: 29298345 ( click the link to review the publication )

PLoS One, 2018, 13(12):e0207934

PubMed: 30543656 ( click the link to review the publication )

PLoS One, 2018, 13(11):e0207399

PubMed: 30444904 ( click the link to review the publication )

Head Neck, 2018, 40(8):1676-1684

PubMed: 29570891 ( click the link to review the publication )

Anal Biochem, 2018, 543:132-139

PubMed: 29247608 ( click the link to review the publication )

SLAS Discov, 2018, 23(6):545-553

PubMed: 29676938 ( click the link to review the publication )

Blood Cells Mol Dis, 2018, 71:23-28

PubMed: 29422232 ( click the link to review the publication )

Oncotarget, 2018, 9(88):35844-35855

PubMed: 30533199 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28456-28473

PubMed: 29983873 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(5):2417-2431

PubMed: 29361132 ( click the link to review the publication )

Oncotarget, 2018, 9(99):37319-37332

PubMed: 30647872 ( click the link to review the publication )

DNA Repair (Amst), 2018, 68:12-24

PubMed: 29807321 ( click the link to review the publication )

Oncotarget, 2018, 9(98):37080-37096

PubMed: 30647846 ( click the link to review the publication )

Oncotarget, 2018, 9(34):23349-23365

PubMed: 29805738 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(2):804-822

PubMed: 29216372 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(18):9537-9549

PubMed: 30137419 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )

J Immunother Cancer, 2018, 6(1):133

PubMed: 30486888 ( click the link to review the publication )

Biochem Biophys Rep, 2018, 16:115-121

PubMed: 30417129 ( click the link to review the publication )

RNA Biol, 2018, 15(11):1420-1432

PubMed: 30362859 ( click the link to review the publication )

Oncotarget, 2018, 9(12):10585-10605

PubMed: 29535829 ( click the link to review the publication )

Sci Transl Med, 2017, 9(375)

PubMed: 28148839 ( click the link to review the publication )
Circ Res, 2017, 120(12):1889-1902

PubMed: 28356339 ( click the link to review the publication )

Blood, 2017, 130(26):2848-2859

PubMed: 29042365 ( click the link to review the publication )

Mol Cell, 2017, 65(5):900-916

PubMed: 28238654 ( click the link to review the publication )

Mol Cell, 2017, 67(3):374-386

PubMed: 28735897 ( click the link to review the publication )

Mol Cell, 2017, 66(5):622-634

PubMed: 28575658 ( click the link to review the publication )

Mol Cell, 2017, 68(2):414-430

PubMed: 29053959 ( click the link to review the publication )

Nat Struct Mol Biol, 2017, 24(11):902-910

PubMed: 28991266 ( click the link to review the publication )

Nat Struct Mol Biol, 2017, 24(9):734-742

PubMed: 28805810 ( click the link to review the publication )

Nat Protoc, 2017, 12(9):1951-1961

PubMed: 28837130 ( click the link to review the publication )

J Clin Invest, 2017, 127(8):3013-3027

PubMed: 28691929 ( click the link to review the publication )

J Clin Invest, 2017, 127(6):2392-2406

PubMed: 28481221 ( click the link to review the publication )

Nat Commun, 2017, 8(1):859

PubMed: 29038466 ( click the link to review the publication )

Nat Commun, 2017, 8:14632

PubMed: 28272405 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(7):3906-3921

PubMed: 28160604 ( click the link to review the publication )

J Thorac Oncol, 2017, 12(8):1309-1319

PubMed: 28389374 ( click the link to review the publication )

EMBO Mol Med, 2017, 9(10):1398-1414

PubMed: 28729482 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(2):514-522

PubMed: 28034904 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(6):1397-1406

PubMed: 27663600 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(4):728-733

PubMed: 28057860 ( click the link to review the publication )

Genes Dev, 2017, 31(1):46-58

PubMed: 28115467 ( click the link to review the publication )

Genes Dev, 2017, 31(3):318-332

PubMed: 28242626 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.30523

PubMed: 29106372 ( click the link to review the publication )

Oncogene, 2017, 36(33):4682-4691

PubMed: 28394338 ( click the link to review the publication )

Cancer Lett, 2017, 398:1-11

PubMed: 28385602 ( click the link to review the publication )
Cancer Lett, 2017, 386:131-140

PubMed: 27894958 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):63

PubMed: 28482906 ( click the link to review the publication )

Cell Death Dis, 2017, 8(1):e2526

PubMed: 28055012 ( click the link to review the publication )

PLoS Genet, 2017, 13(10):e1007031

PubMed: 28968398 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1934-1941

PubMed: 28522591 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(12):2892-2901

PubMed: 28958991 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):2022-2034

PubMed: 28619759 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-16-0740

PubMed: 28500233 ( click the link to review the publication )

Mol Oncol, 2017, 11(5):470-490

PubMed: 28173629 ( click the link to review the publication )

Oncol Res, 2017, 25(9):1441-1451

PubMed: 28429680 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(1):45-58

PubMed: 27671334 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(3):269-280

PubMed: 28074003 ( click the link to review the publication )

Sci Rep, 2017, 7(1):12876

PubMed: 28993682 ( click the link to review the publication )

Virology, 2017, 507:220-230

PubMed: 28456021 ( click the link to review the publication )

Cancer Biol Ther, 2017, 18(9):694-704

PubMed: 28886275 ( click the link to review the publication )

Cell Cycle, 2017, 16(11):1128-1135

PubMed: 28463527 ( click the link to review the publication )

Transl Oncol, 2017, 10(2):190-196

PubMed: 28182994 ( click the link to review the publication )

Oncol Res, 2017, 25(9):1441-1451

PubMed: 28429680 ( click the link to review the publication )

PLoS One, 2017, 12(9):e0184619

PubMed: 28886188 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(11):2705-2716

PubMed: 28394191 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 488(1):211-217

PubMed: 28487110 ( click the link to review the publication )

Int J Med Sci, 2017, 14(12):1292-1300

PubMed: 29104487 ( click the link to review the publication )

Mol Med Rep, 2017, 16(1):208-214

PubMed: 28498459 ( click the link to review the publication )

Cancer Biother Radiopharm, 2017, 32(1):9-15

PubMed: 28118040 ( click the link to review the publication )
Oncotarget, 2017, 8(67):111026-111040

PubMed: 29340034 ( click the link to review the publication )

Oncotarget, 2017, 8(53):90662-90673

PubMed: 29207595 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(18):10614-10633

PubMed: 28977657 ( click the link to review the publication )

Oncotarget, 2017, 8(8):13223-13239

PubMed: 28099939 ( click the link to review the publication )

Tumour Biol, 2017, 39(10):1010428317713390

PubMed: 29064327 ( click the link to review the publication )

Oncotarget, 2017, 8(40):68707-68720

PubMed: 28978150 ( click the link to review the publication )

Oncotarget, 2017, 8(67):111026-111040

PubMed: 29340034 ( click the link to review the publication )

Oncotarget, 2017, 8(53):90842-90851

PubMed: 29207607 ( click the link to review the publication )

Oncotarget, 2017, 8(55):94505-94518

PubMed: 29212245 ( click the link to review the publication )

Oncotarget, 2017, 8(18):29963-29975

PubMed: 28415784 ( click the link to review the publication )

Tumour Biol, 2017, 39(10):1010428317713390

PubMed: 29064327 ( click the link to review the publication )

Nucleic Acids Res, 2017, 45(7):3844-3859

PubMed: 28158503 ( click the link to review the publication )

Blood Adv, 2017, 1(19):1467-1472

PubMed: 29296788 ( click the link to review the publication )

Oncotarget, 2017, 8(61):103931-103951

PubMed: 29262611 ( click the link to review the publication )

Oncotarget, 2017, 8(19):31815-31829

PubMed: 28415632 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28489577 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29285242 ( click the link to review the publication )

Oncotarget, 2017, 8(40):68707-68720

PubMed: 28978150 ( click the link to review the publication )

Oncotarget, 2017, 8(25):40152-40168

PubMed: 27374179 ( click the link to review the publication )

Oncotarget, 2017, 8(49):86799-86815

PubMed: 29156836 ( click the link to review the publication )

Oncotarget, 2017, 8(44):76935-76948

PubMed: 29100359 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(12):1357-1366

PubMed: 27820601 ( click the link to review the publication )

Blood, 2016, 127(1):139-48

PubMed: 26463424 ( click the link to review the publication )

Nat Struct Mol Biol, 2016, 23(7):647-55

PubMed: 27239795 ( click the link to review the publication )
J Clin Invest, 2016, 126(8):2903-18

PubMed: 27454287 ( click the link to review the publication )

Nat Commun, 2016, 7:13837

PubMed: 27958275 ( click the link to review the publication )

Nat Commun, 2016, 7:12425

PubMed: 27498558 ( click the link to review the publication )

Nucleic Acids Res, 2016, 45(5):2546-2557

PubMed: 27965414 ( click the link to review the publication )

EMBO J, 2016, 35(14):1488-503

PubMed: 27225932 ( click the link to review the publication )

Cancer Res, 2016, 76(9):2778-90

PubMed: 27197267 ( click the link to review the publication )

Theranostics, 2016, 6(11):1821-32

PubMed: 27570553 ( click the link to review the publication )

Cancer Res, 2016, 76(10):3067-77

PubMed: 26980768 ( click the link to review the publication )

Cell Rep, 2016, 17(9):2367-2381

PubMed: 27880910 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.13620

PubMed: 27336789 ( click the link to review the publication )

J Invest Dermatol, 2016, 136(6):1219-1228

PubMed: 26880244 ( click the link to review the publication )

Diabetologia, 2016, 59(11):2360-2368

PubMed: 27539148 ( click the link to review the publication )

Br J Cancer, 2016, 114(7):777-86

PubMed: 26964031 ( click the link to review the publication )

PLoS Genet, 2016, 12(9):e1006279

PubMed: 27588951 ( click the link to review the publication )

PLoS Genet, 2016, 12(1):e1005816

PubMed: 26820313 ( click the link to review the publication )

Bioinformatics, 2016, 32(12):i253-i261

PubMed: 27307624 ( click the link to review the publication )

Gynecol Oncol, 2016, 142(2):323-31

PubMed: 27282964 ( click the link to review the publication )

DNA Repair , 2016, 10.1016/j.dnarep.2016.06.001

PubMed: 27373144 ( click the link to review the publication )

Sci Rep, 2016, 6:19567

PubMed: 26777522 ( click the link to review the publication )

Analyst, 2016, 141(8):2454-62

PubMed: 26974179 ( click the link to review the publication )

Mediators Inflamm, 2016, 2016:1984703

PubMed: 27524861 ( click the link to review the publication )

Cell Cycle, 2016, 15(22):3105-3114

PubMed: 27686740 ( click the link to review the publication )

BMC Cancer, 2016, 16:621

PubMed: 27515310 ( click the link to review the publication )

BMC Cancer, 2016, 16(1):851

PubMed: 27816051 ( click the link to review the publication )
BMC Cancer, 2016, 16(1):725

PubMed: 27613518 ( click the link to review the publication )

BMC Cancer, 2016, 16:550

PubMed: 27465688 ( click the link to review the publication )

Eur J Pharmacol, 2016, 791:444-454

PubMed: 27612628 ( click the link to review the publication )

Bioorg Med Chem, 2016, 24(5):1071-8

PubMed: 26833244 ( click the link to review the publication )

Neurochem Res, 2016, 41(7):1516-26

PubMed: 26869042 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0146031

PubMed: 26730949 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(1):234-240

PubMed: 27425251 ( click the link to review the publication )

Anal Biochem, 2016, 503:58-64

PubMed: 27036617 ( click the link to review the publication )

Nucl Med Biol, 2016, 43(12):752-758

PubMed: 27689533 ( click the link to review the publication )

Target Oncol, 2016, 11(5):655-665

PubMed: 27188390 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 26943587 ( click the link to review the publication )

Oncotarget, 2016, 7(7):7701-14

PubMed: 26713604 ( click the link to review the publication )

Eur J Pharmacol, 2016, 791:444-454

PubMed: 27612628 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13984-4001

PubMed: 26910887 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2016, 95(2):772-81

PubMed: 27020103 ( click the link to review the publication )

Nucleic Acids Res, 2016, 44(3):1161-78

PubMed: 26578593 ( click the link to review the publication )

Oncotarget, 2016, 7(9):9732-41

PubMed: 26799421 ( click the link to review the publication )

Zhongguo Fei Ai Za Zhi, 2016, 19(1):16-23

PubMed: 26805733 ( click the link to review the publication )

Oncotarget, 2016, 7(22):32980-9

PubMed: 27145275 ( click the link to review the publication )

Oncotarget, 2016, 7(46):75551-75560

PubMed: 27705909 ( click the link to review the publication )

Oncotarget, 2016, 7(15):20825-39

PubMed: 26959114 ( click the link to review the publication )

EMBO Rep, 2015, 16(11):1520-34

PubMed: 26412854 ( click the link to review the publication )

Cell Rep, 2015, 13(8):1623-32

PubMed: 26586427 ( click the link to review the publication )

Mol Cancer, 2015, 14:114

PubMed: 26041471 ( click the link to review the publication )
Nanoscale, 2015, 7(6):2805-11

PubMed: 25584654 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.212

PubMed: 26073085 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.443

PubMed: 25619829 ( click the link to review the publication )

PLoS Genet, 2015, 11(1):e1004943

PubMed: 25629353 ( click the link to review the publication )

PLoS Genet, 2015, 11(7):e1005384

PubMed: 26181065 ( click the link to review the publication )

PLoS Genet, 2015, 11(10):e1005563

PubMed: 26430909 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(11):2560-8

PubMed: 26351319 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2818-30

PubMed: 26438158 ( click the link to review the publication )

Mol Cancer Ther, 2015, 10.1158/1535-7163.MCT-14-0810

PubMed: 25777962 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(11):1465-77

PubMed: 26217019 ( click the link to review the publication )

Mol Cancer Res, 2015, 13(10):1389-97

PubMed: 26116172 ( click the link to review the publication )

Front Oncol, 2015, 5:191

PubMed: 26380221 ( click the link to review the publication )

J Transl Med, 2015, 13:239

PubMed: 26198537 ( click the link to review the publication )

J Transl Med, 2015, 13:225

PubMed: 26169874 ( click the link to review the publication )

J Transl Med, 2015, 13:233

PubMed: 26183824 ( click the link to review the publication )

Sci Rep, 2015, 5:11465

PubMed: 26095524 ( click the link to review the publication )

Sci Rep, 2015, 5:10129

PubMed: 25984718 ( click the link to review the publication )

Front Microbiol, 2015, 6:878

PubMed: 26379653 ( click the link to review the publication )

Biochem J, 2015, 469(2):189-98

PubMed: 25940138 ( click the link to review the publication )

Mol Cell Biol, 2015, 35(23):3934-44

PubMed: 26370511 ( click the link to review the publication )

Int J Oncol, 2015, 47(1):262-8

PubMed: 25975349 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):752-67

PubMed: 26069190 ( click the link to review the publication )

Cell Cycle, 2015, 14(20):3261-9

PubMed: 26317799 ( click the link to review the publication )

Cell Cycle, 2015, 14(20):3248-60

PubMed: 26312527 ( click the link to review the publication )
BMC Cancer, 2015, 15:89

PubMed: 25884663 ( click the link to review the publication )

BMC Cancer, 2015, 15(1):1090

PubMed: 25777417 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:3183-90

PubMed: 26124641 ( click the link to review the publication )

Dis Esophagus, 2015, 10.1111/dote.12299

PubMed: 25604309 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 460(2):183-90

PubMed: 25767076 ( click the link to review the publication )

Onco Targets Ther, 2015, 8:3047-54

PubMed: 26543375 ( click the link to review the publication )

Mol Cell Biochem, 2015, 400(1-2):153-62

PubMed: 25404465 ( click the link to review the publication )

J Breast Cancer, 2015, 18(4):329-38

PubMed: 26770239 ( click the link to review the publication )

Oncol Lett, 2015, 9(2):757-761

PubMed: 25621047 ( click the link to review the publication )

J Vet Emerg Crit Care (San Antonio), 2015, 25(4):528-37

PubMed: 26040949 ( click the link to review the publication )

Oncotarget, 2015, 6(14):12697-709

PubMed: 25885523 ( click the link to review the publication )

Oncotarget, 2015, 6(13):10746-58

PubMed: 25883215 ( click the link to review the publication )

Oncotarget, 2015, 6(38):41307-23

PubMed: 26513298 ( click the link to review the publication )

Nucleic Acids Res, 2015, 43(14):6934-44

PubMed: 26130715 ( click the link to review the publication )

Oncotarget, 2015, 6(41):43679-97

PubMed: 26544897 ( click the link to review the publication )

Oncotarget, 2015, 6(38):41307-23

PubMed: 26513298 ( click the link to review the publication )

DNA Repair (Amst), 2015, 35:106-15

PubMed: 26519824 ( click the link to review the publication )

DNA Repair (Amst), 2015, 26:23-9

PubMed: 25541391 ( click the link to review the publication )

Princeton University, 2015, 88435/dsp01br86b5821

PubMed: ( click the link to review the publication )

Cell, 2015, 161(7):1592-605

PubMed: 26052046 ( click the link to review the publication )

Oncotarget, 2015, 6(42):44819-31

PubMed: 26540566 ( click the link to review the publication )

Front Oncol, 2015, 5:191

PubMed: 26380221 ( click the link to review the publication )

Sci Transl Med, 2014, 6(222):222ra18

PubMed: 24500406 ( click the link to review the publication )

Nat Commun, 2014, 5:5496

PubMed: 25400221 ( click the link to review the publication )
Nat Commun, 2014, 5:3361

PubMed: 24553445 ( click the link to review the publication )

J Clin Invest, 2014, 124(7):3061-74

PubMed: 24911143 ( click the link to review the publication )

Nat Commun, 2014, 5:3946

PubMed: 24867710 ( click the link to review the publication )

Nucleic Acids Res, 2014, 42(11):7028-38

PubMed: 24861619 ( click the link to review the publication )

Cancer Res, 2014, 74(21):5948-54

PubMed: 25145669 ( click the link to review the publication )

Cell Rep, 2014, 8(6):1808-18

PubMed: 25199834 ( click the link to review the publication )

Cell Death Differ, 2014, 21(2):258-69

PubMed: 24121277 ( click the link to review the publication )

Eur J Cancer, 2014, 50(15):2725-34

PubMed: 25128455 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):20-8

PubMed: 24534203 ( click the link to review the publication )

Sci Signal, 2014, 7(326):ra47

PubMed: 24847116 ( click the link to review the publication )

J Med Chem, 2014, 57(13):5579-601

PubMed: 24922587 ( click the link to review the publication )

PLoS Pathog, 2014, 10(12):e1004536

PubMed: 25474690 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(2):R25

PubMed: 24625110 ( click the link to review the publication )

J Cereb Blood Flow Metab, 2014, 127(23):5079-92

PubMed: 25248836 ( click the link to review the publication )

J Neuroscience, 2014, 34(28):9338-50

PubMed: 25009267 ( click the link to review the publication )

Arch Toxicol, 2014, 10.1007/s00204-014-1434-0

PubMed: 25526924 ( click the link to review the publication )

PLoS Genet, 2014, 10(10):e1004654

PubMed: 25275444 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(6):1645-54

PubMed: 24694947 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(3):724-32

PubMed: 24356817 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(4):986-95

PubMed: 24552776 ( click the link to review the publication )

Mol Oncol, 2014, 10.1016/j.molonc.2014.07.022

PubMed: 25139258 ( click the link to review the publication )

Mol Oncol, 2014, S1574-7891(14)00132-X

PubMed: 25028150 ( click the link to review the publication )

Radiother Oncol, 2014, 113(3):345-51

PubMed: 25467050 ( click the link to review the publication )

Oral Oncol, 2014, 50(9):825-31

PubMed: 25017803 ( click the link to review the publication )
Cancer Sci, 2014, 105(2):202-10

PubMed: 24219164 ( click the link to review the publication )

J Cell Mol Med, 2014, 18(1):143-55

PubMed: 24238094 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1852(3):462-472

PubMed: 25483710 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1843(11):2662-2673

PubMed: 25072752 ( click the link to review the publication )

Biochim Biophys Acta, 2014, 1844(10):1765-72

PubMed: 25062913 ( click the link to review the publication )

J Trans Med, 2014, 12(1):184

PubMed: 24965603 ( click the link to review the publication )

Mol Pharmacol, 2014, 9(4):e95649

PubMed: 24748377 ( click the link to review the publication )

Int J Oncol, 2014, 44(3):735-44

PubMed: 24378347 ( click the link to review the publication )

Cell Cycle, 2014, 13(11):1708-16

PubMed: 24675890 ( click the link to review the publication )

Cell Cycle, 2014, 12(11):1679-87

PubMed: 23656790 ( click the link to review the publication )

J Pharm Sci, 2014, 103(6):1913-20

PubMed: 24700236 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108731

PubMed: 25264618 ( click the link to review the publication )

J Cardiovasc Pharmacol, 2014, 10.1038/onc.2014.105

PubMed: 24769898 ( click the link to review the publication )

Medicine, 2014, 93(28):e294

PubMed: 25526472 ( click the link to review the publication )

Oncol Lett, 2014, 8(3):1222-1228

PubMed: 25120693 ( click the link to review the publication )

Oncotarget, 2014, 5(10):3023-8

PubMed: 24632590 ( click the link to review the publication )

Nat Struct Mol Biol, 2013, 20(3):347-54

PubMed: 23396353 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(18):5003-15

PubMed: 23881923 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 12(7):529-34

PubMed: 23684799 ( click the link to review the publication )

Cancer Res, 2013, 72(11):2814-21

PubMed: 22447567 ( click the link to review the publication )

Cancer Res, 2013, 74(1):287-97

PubMed: 24240700 ( click the link to review the publication )

Oncogene, 2013, 32(47):5377-87

PubMed: 23934192 ( click the link to review the publication )

Cancer Lett, 2013, 343(2):217-23

PubMed: 24215868 ( click the link to review the publication )

J Exp Clin Cancer Res, 2013, 32(1):95

PubMed: 24252502 ( click the link to review the publication )
FASEB J, 2013, 27(6):2316-27

PubMed: 23444429 ( click the link to review the publication )

PLoS Genet, 2013, 9(6):e1003531

PubMed: 23785295 ( click the link to review the publication )

Mol Oncol, 2013, 7(3):567-79

PubMed: 23415752 ( click the link to review the publication )

Carcinogenesis, 2013, 34(4):739-49

PubMed: 23275151 ( click the link to review the publication )

Neoplasia, 2013, 15(6):600-8

PubMed: 23730208 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1179-92

PubMed: 23913164 ( click the link to review the publication )

DNA Repair , 2013, 12(12):1134-42

PubMed: 24210699 ( click the link to review the publication )

J Viral Hepat, 2013, 20(9):658-65

PubMed: 23910651 ( click the link to review the publication )

J Biol Chem, 2013, 288(10):7086-95

PubMed: 23355489 ( click the link to review the publication )

Cancer Biol Ther, 2013, 14(6):537-45

PubMed: 23760496 ( click the link to review the publication )

PLoS One, 2013, 8(6):e66130

PubMed: 23762475 ( click the link to review the publication )

J Mass Spectrom, 2013, 48(12):1285-90

PubMed: 24338883 ( click the link to review the publication )

DNA Repair (Amst), 2013, 12(6):394-402

PubMed: 23570906 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(22):10268-82

PubMed: 23997120 ( click the link to review the publication )

Hepatology, 2012, 55(6):1840-51

PubMed: 22223166 ( click the link to review the publication )

Nat Struct Mol Biol, 2012, 19(4):417-23

PubMed: 22388737 ( click the link to review the publication )

EMBO Mol Med, 2012, 4(10):1087-96

PubMed: 22933245 ( click the link to review the publication )

Oncogene, 2012, 32(39):4634-45

PubMed: 23108394 ( click the link to review the publication )

Cancer Lett, 2012, 319(2):232-41

PubMed: 22266096 ( click the link to review the publication )

J Med Chem, 2012, 55(7):3011-20

PubMed: 22380680 ( click the link to review the publication )

PLoS Genet, 2012, 8(3):e1002574

PubMed: 22412391 ( click the link to review the publication )

Neoplasia, 2012, 14(3):169-77

PubMed: 22496617 ( click the link to review the publication )

DNA Repair , 2012, 11(6):537-49

PubMed: 22542292 ( click the link to review the publication )

Cancer Sci, 2012, 103(6):1045-50

PubMed: 22404155 ( click the link to review the publication )
J Biol Chem, 2012, 287(47):39824-33

PubMed: 21956491 ( click the link to review the publication )

J Biol Chem, 2012, 287(44):36777-91

PubMed: 22961983 ( click the link to review the publication )

J Biol Chem, 2012, 287(52):43720-9

PubMed: 23105099 ( click the link to review the publication )

PLoS One, 2012, 7(6):e39956

PubMed: 22768182 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2012, 84(3):815-21

PubMed: 22417805 ( click the link to review the publication )

ACS Nano, 2011, 5(11):9216-24

PubMed: 21962084 ( click the link to review the publication )

J Biol Chem, 2011, 286(14):12157-65

PubMed: 21285347 ( click the link to review the publication )

Mol Cell Biol, 2011, 31(12):2462-9

PubMed: 21482670 ( click the link to review the publication )

PLoS One, 2011, 6(11):e27183

PubMed: 22073281 ( click the link to review the publication )

EMBO Rep, 2010, 11(12):962-8

PubMed: 21052091 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description

Features

A potent PARP inhibitor (currently in late stage clinical trials).

Targets

PARP2 ^[1] (Cell-free assay)	PARP1 ^[1] (Cell-free assay)
1 nM	5 nM

In vitro

Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). ^[1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
KP3.33	NWWxcWhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmPTOEBl		NFn6TnVKSzVyPUWuO\|A2KCEQvF2g	NUfFc5hTOTh3NUm2NVM>
KP6.3	NWW3UXQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MWS0JIQ>		Mn\mTWM2OD1zMD60Nlgh\|ryPIB?=	NEXQWo8yQDV3OU[xNy=>
KP7.7	NYL5OHd7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MX:0JIQ>		M3LPdGlEPTB;NUegcm0h	NHuxO3AyQDV3OU[xNy=>
KB2P3.4	NYjoc5FYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MY[0JIQ>		NFfuOYpKSzVyPUGyOEBOKA>?	NV;1c4V3OTh3NUm2NVM>
KB2P1.21	M3v6e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnHkOEBl		MmHMTWM2OD16OUC3JI5OKA>?	NV21Um14OTh3NUm2NVM>
U373-MG	Mn3qR5l1d3SxeHnjJGF{e2G7	MVexJO69VSB?	NVe0TYpDOjRiaB?=		NV;FXZRzUW6lcnXhd4V{KHKjZHnheIlwdiC\|ZX7zbZRqfmm2eR?=	NYLDUo1ROTh7NUS3NVI>
T98G	MoDYR5l1d3SxeHnjJGF{e2G7	NFPFenkyKM7:TTC=	NV;GbG1kOjRiaB?=		Mkm4TY5kemWjc3XzJJJi\GmjdHnvckB{\W6\|aYTpeol1gQ>?	NEnGfXEyQDl3NEexNi=>
U87-MG	NEnqVHVEgXSxdH;4bYMhSXO\|YYm=	MUGxJO69VSB?	NHP0cHUzPCCq		NXXnSZJxUW6lcnXhd4V{KHKjZHnheIlwdiC\|ZX7zbZRqfmm2eR?=	MVyxPFk2PDdzMh?=
UVW	NInrfZZEgXSxdH;4bYMhSXO\|YYm=	MY[1NFAhdk1?	MViyOEBp		MkC4TY5kemWjc3XzJJJi\GmjdHnvckB{\W6\|aYTpeol1gQ>?	NWDYWGlTOTh7NUS3NVI>
HeLa	NUH5ZWpWTnWwY4Tpc44hSXO\|YYm=	MU[1NFAhdk1?	NYjR[YlUPCCq		NI\sUZRE[XW\|ZYOgZUBud2Snc4Sg[IVt[XliaX6gdoVrd2mwaX7nJI9nKHKjZHnheIlwdi2rbnT1Z4VlKESQQTDidoVic3N?	NWrMWpA4OTh7NUS3NVI>
HeLa	MVTGeY5kfGmxbjDBd5NigQ>?	MV:xJO69VSB?	NET0clYzPCCq		NW\iUYU4TW6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhWy2yaHHz[UBienKnc4S=	NXP5UZRzOTh7NUS3NVI>
T98G	M{T2NmZ2dmO2aX;uJGF{e2G7	M{f3WlEh\|ryPIB?=	MYeyOEBp		NYnadmFqTW6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhWy2yaHHz[UBienKnc4S=	Mnn2NVg6PTR5MUK=
L3	MUHDfZRwfG:6aXOgRZN{[Xl?	M{DMdFUh\|ryPIB?=	M4HIVVk3KGh?	NGeySoxFVVOR	M2fB[nNq\26rZnnjZY51dHliaX7obYJqfHNiY3XscEB{fXK4aY\hcC=>	MXKyNFEzPDR3OR?=
Granta-519	NIjKT29EgXSxdH;4bYMhSXO\|YYm=	MUi1JO69VSB?	NXvMeFBMQTZiaB?=	NHTG[lFFVVOR	M4XiTXNtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx?	MVeyNFEzPDR3OR?=
BT	NVHneYJqS3m2b4TvfIlkKEG\|c3H5	MmX1OUDPxE1i	NGf1TG46PiCq	M{[xZmROW09?	Mo\xV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC\|dYL2bZZidA>?	NYLBNXJIOjBzMkS0OVk>
UPN2	M3;IbGN6fG:2b4jpZ{BCe3OjeR?=	M3T4RVUh\|ryPIB?=	NU\Ie3BZQTZiaB?=	MVPEUXNQ	M3\Z[3NtcWeqdHz5JIlvcGmkaYTzJINmdGxic4Xyeol3[Wx?	MUOyNFEzPDR3OR?=
HBL-2	NWLV[o5LS3m2b4TvfIlkKEG\|c3H5	NX3veFAzPSEQvF2g	M3\m[\|k3KGh?	MYHEUXNQ	NIHqNpdUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu	NEL4PXozODF{NES1PS=>
JVM-2	MXnDfZRwfG:6aXOgRZN{[Xl?	NFzadWU2KM7:TTC=	Mke2PVYhcA>?	NXG1VWlMTE2VTx?=	NHHk[WdUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu	NXLUN\|JkOjBzMkS0OVk>
Z138	NWLpU3VuS3m2b4TvfIlkKEG\|c3H5	NGnPRnk2KM7:TTC=	M4PKUFk3KGh?	MnK3SG1UVw>?	NFW3dHRUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu	MViyNFEzPDR3OR?=
RWPE	MlLJTY53[XOrdnWgRZN{[Xl?	NYO4[W93OjVizszN	M2HVO\|Q5KGh?	MmrySG1UVw>?	NXzlW4U6W2mpbnnmbYNidnSueTDy[YR2[2W\|IFXSS{1lemm4ZX6gZ4VtdCCrbo\hd4lwdg>?	M{nMUVIyPTd3OE[1
VCaP	MnLrTY53[XOrdnWgRZN{[Xl?	NEXqd5YzPSEQvF2=	Mln1OFghcA>?	M1PRWGROW09?	NHTwV21UcWewaX\pZ4FvfGy7IILl[JVk\XNiRWLHMYRzcX[nbjDj[YxtKGmwdnHzbY9v	NFHOeJgzOTV5NUi2OS=>
Mouse H2AX−/− ES Cells	NI[1XItEgXSxdH;4bYMhSXO\|YYm=	M4LEVlIvPSEQvF2=	MmXnNlAhcA>?		MmPPV4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJJN2en[rdnHs	NWDhZWE6OjN\|NUW0PFk>
Mouse ATM−/− ES Cells	NHL3UXVEgXSxdH;4bYMhSXO\|YYm=	MnnkNk42KM7:TR?=	MnnZNlAhcA>?		MmTwV4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJJN2en[rdnHs	MVKyN\|M2PTR6OR?=
H1650	Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjzXZAzOCEQvF2=	MmPzNVQ1KGh?		MmLSTWM2OD1zNT60O{DPxE1?	NGmwWnQzOzJ\|OUiwPS=>
H1650PTEN+	MorVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkLJNlAh\|ryP	NV3RTGFoOTR2IHi=		MkX5TWM2OD13MD64N{DPxE1?	NE\TW5AzOzJ\|OUiwPS=>
PC-9	Mm\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlH2NlAh\|ryP	MYSxOFQhcA>?		MWnJR\|UxRTVwOEig{txO	MmH5NlMzOzl6MEm=
PC-9PTEN−	NHmxNpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYKyNEDPxE1?	Mke3NVQ1KGh?		NVPJZo5qUUN3ME22MlUzKM7:TR?=	NUDTTFlCOjN{M{m4NFk>
MDA-MB-231	M3TMWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NU[1R\|RRPSCmYYm=		M3:3VGlEPTB;Nj65JO69VQ>?	M3ruc\|I{PzZyNEm2
MDA-MB-468	M4TNZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUHtT2Y{PSCmYYm=		NF3hbppKSzVyPUWuNEDPxE1?	NWTKcWI{OjN5NkC0PVY>
BT20	M4W5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mkf3OUBl[Xl?		M3LKN2lEPTB;Nz63JO69VQ>?	MmHsNlM4PjB2OU[=
HCC1143	Mn3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NV7r[FBUPSCmYYm=		Mn;vTWM2OD1zMT6xJO69VQ>?	NFX0bZAzOzd4MES5Oi=>
HCC1937	M1X2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHXkWXE2KGSjeR?=		MYPJR\|UxRTF{Lk[g{txO	MlrGNlM4PjB2OU[=
Hs578t	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGH1NJQ2KGSjeR?=		MnrwTWM2OD13Lk[g{txO	MlXMNlM4PjB2OU[=
Hs578t(si)	NWK0bnNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnL1OUBl[Xl?		NUj4cYFoUUN3ME23MlUh\|ryP	M1jlblI{PzZyNEm2
BT474	MknCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUW1JIRigQ>?		M1LBZmlEPTB;MUmuPEDPxE1?	MUKyN\|c3ODR7Nh?=
JIMT1	NHj3cHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1\aWFUh\GG7		NYPGUFZUUUN3ME23Mlch\|ryP	MoPCNlM4PjB2OU[=
SKBR3	MljXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIC3W\|M2KGSjeR?=		NIL2U5NKSzVyPUGxMlEh\|ryP	MnriNlM4PjB2OU[=
SUM159	MkjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mkf2OUBl[Xl?		NHvxN2xKSzVyPUSuNkDPxE1?	M{m1OlI{PzZyNEm2
CAMA1	MojJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NYLJRYlPPSCmYYm=		NWfi[VVZUUN3ME2xOU45KM7:TR?=	NHLGelIzOzd4MES5Oi=>
MCF7	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVq1JIRigQ>?		MUjJR\|UxRTVwODFOwG0>	MWmyN\|c3ODR7Nh?=
T47D	M2HhcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUi1JIRigQ>?		MUPJR\|UxRTlwNjFOwG0>	MoixNlM4PjB2OU[=
HCT116	M2Hv[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXixNFAh\|ryP	NIe5T4U1QCCq	NFflboZFVVOR	Mor3TWM2OD1{LkWg{txOKA>?	MX:yOFU4Pzl2MR?=
SW1116	NH\wWo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrjNVAxKM7:TR?=	NIq0UYs1QCCq	MYHEUXNQ	MmDUTWM2OD1zMECg{txO	MkDqNlQ2Pzd7NEG=
HT29	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jGUFExOCEQvF2=	MnfhOFghcA>?	M2jwU2ROW09?	NUTtVllkUUN3ME2xOE44KM7:TR?=	NIrjTlAzPDV5N{m0NS=>
LoVo	MlrHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXWxNFAh\|ryP	Mn7aOFghcA>?	NEDOWlJFVVOR	MWTJR\|UxRTF\|LkSg{txO	M1HmPFI1PTd5OUSx
HCT-15	MoPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3vWWlExOCEQvF2=	NYGzPHVkPDhiaB?=	NGPoZnRFVVOR	M{XZd2lEPTB;MUCg{txO	MmjyNlQ2Pzd7NEG=
SW48	M2Lmcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;VdYRCOTByIN88US=>	MVO0PEBp	NXu5bG8{TE2VTx?=	MnTZTWM2OD17LkWg{txO	M17tTlI1PTd5OUSx
C-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\tN5duOTByIN88US=>	Mn;IOFghcA>?	NVe0TppVTE2VTx?=	NVfQTlRlUUN3ME23MlYh\|ryP	NXzKR2VUOjR3N{e5OFE>
RKO	NFP1OYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLyNVAxKM7:TR?=	M{LU[VQ5KGh?	NYXKXZFRTE2VTx?=	NIH3WFBKSzVyPUWuPUDPxE1?	Mnu0NlQ2Pzd7NEG=
HCT116	Ml3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUC5O\|ByOTByIN88US=>	NYDOPVFnPDhiaB?=	NUH3PZRoTE2VTx?=	NUXpR5Y6WG:2ZX70bYF1\XNiU16tN\|gh[3m2b4TvfIlkcXS7IB?=	MYWyOFU4Pzl2MR?=
SW1116	M4fKPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLDNVAxKM7:TR?=	M{K1PVQ5KGh?	NHi1cIxFVVOR	MnLYVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>?	MlTMNlQ2Pzd7NEG=
HT29	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XSOlExOCEQvF2=	MWm0PEBp	MVrEUXNQ	NVfWfot3WG:2ZX70bYF1\XNiU16tN\|gh[3m2b4TvfIlkcXS7IB?=	M1\TR\|I1PTd5OUSx
LoVo	NImxbXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYKxNFAh\|ryP	NXfJcW95PDhiaB?=	NXrzUYN7TE2VTx?=	M2fMO3BwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB?	MlWxNlQ2Pzd7NEG=
SW48	NHrhU5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUPC[ZRROTByIN88US=>	M1G2clQ5KGh?	NIj3[oVFVVOR	Mlz2VI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>?	M4rYVFI1PTd5OUSx
C-1	MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHDeVcyODBizszN	NHjUc5M1QCCq	MnLhSG1UVw>?	MYDQc5RmdnSrYYTld{BUVi1\|ODDjfZRwfG:6aXPpeJkh	Mnn3NlQ2Pzd7NEG=
RKO	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jOVFExOCEQvF2=	M4G4WFQ5KGh?	NXvxfWtLTE2VTx?=	NHPYT4RRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli	MWKyOFU4Pzl2MR?=
HCT116	NXPPZnZtTnWwY4Tpc44hSXO\|YYm=	M{GzWFExKG6P	MnjtNVIhcA>?	MlOzSG1UVw>?	NXi4[mNCUW6lcnXhd4V{KESQQTDkc5VjdGVvc4TyZY5lKGK{ZXHrd{BqdmS3Y3XkJIJ6KFOQLUO4	NUPRU\|Q3OjR3N{e5OFE>
HT29	MXXGeY5kfGmxbjDBd5NigQ>?	NYjmcJZHOTBibl2=	Mnn5NVIhcA>?	NWC5R5JpTE2VTx?=	NGPvSXJKdmO{ZXHz[ZMhTE6DIHTveYJt\S2\|dILhcoQh[nKnYXvzJIlv\HWlZXSgZpkhW05vM{i=	MWOyOFU4Pzl2MR?=
TE-6	M1fafWZ2dmO2aX;uJGF{e2G7	MY[1JO69VSB?	MnnENVIhcA>?	M3fCeWROW09?	MnzMTY5lfWOnczDHNk9OKGG{cnXzeC=>	NYfuU3k5OjR{MUmxOlQ>
TE-6	MV;GeY5kfGmxbjDBd5NigQ>?	MUC1JO69VSB?	MWiyOEBp	NXjHT4JxTE2VTx?=	MXLJcoNz\WG\|ZYOgbY4h\G:3YnzlJJN1emGwZDDidoVic3NiKFTTRpMq	Ml7uNlQzOTlzNkS=
Hep3B	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PkS\|QxKM7:TTC=	MkHFO\|IhcA>?	NE\JS\|FFVVOR	MVPTfY5memerc4TpZ4FtdHliaX7obYJqfHNiY3XscEBoem:5dHige4l1cCCGSF3FVS=>	MXiyOVA4Ojd3Mh?=
Huh7	NUnNb3RLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU[0NEDPxE1i	M2HnOVczKGh?	MUHEUXNQ	M3XkZnN6dmW{Z3nzeIlk[WyueTDpcohq[mm2czDj[YxtKGe{b4f0bEB4cXSqIFTIUWVS	MmPNNlUxPzJ5NUK=
Hep3B	MYTGeY5kfGmxbjDBd5NigQ>?	NID3U3E1OCEQvF2g	M2nN[VI1KGh?	MlS2SG1UVw>?	MljlTY5lfWOnczDSU3MheHKxZIXjeIlwdiC5aYToJGRJVUWT	M1P1dFI2ODd{N{Wy
Huh7	NFS4[HJHfW6ldHnvckBCe3OjeR?=	Mn7lOFAh\|ryPIB?=	MWGyOEBp	NUP1VFJWTE2VTx?=	M3XXZWlv\HWlZYOgVm9UKHC{b3T1Z5Rqd25id3n0bEBFUE2HUR?=	M4ixd\|I2ODd{N{Wy
Hep3B	NFHHVJFHfW6ldHnvckBCe3OjeR?=	NUPyW\|FZPDBizszNJC=>	NFG4[3ozPCCq	M4\iTGROW09?	MkW2TY5lfWOnczDj[YxtKGG3dH;wbIFogSC5aYToJGRJVUWT	NELTW3AzPTB5Mke1Ni=>
Huh7	NGC1eJZHfW6ldHnvckBCe3OjeR?=	NEnIcIg1OCEQvF2g	NGjLd2MzPCCq	M1LnSWROW09?	NUPoRpZJUW6mdXPld{Bk\WyuIHH1eI9xcGGpeTD3bZRpKESKTVXR	NGTH[JozPTB5Mke1Ni=>
SGC-7901	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXiN\|DDqM7:TR?=	M2exWVQ5KGh?	M3j6UmROW09?	Mlm3Roxw[2tib4jhcIlxdGG2aX6tbY5lfWOnZDDj[YxtKGSnYYTo	MmixNlU4PjdyN{[=
COLO-800	MorlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHmTWM2OD1yLkS0NVY1KM7:TR?=	MkL3V2FPT0WU
EoL-1-	NFXuPWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGXUdZdKSzVyPUCuOVY1PDZizszN	M4Xq[3NCVkeHUh?=
NCI-H209	M2jiVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHniR2JKSzVyPUCuPVE2PTZizszN	NWXifVNwW0GQR1XS
ES1	MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLYTWM2OD1zLkGxOFA5KM7:TR?=	MUHTRW5ITVJ?
NKM-1	M4TiXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWnQbGpWUUN3ME2xMlI2OzR5IN88US=>	NFLpXIpUSU6JRWK=
NTERA-S-cl-D1	NVzYcFZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXj5V3l{UUN3ME2xMlM{OzRzIN88US=>	NV3jT\|VPW0GQR1XS
MHH-ES-1	M1;uemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTFwNkKwOlch\|ryP	M2rySXNCVkeHUh?=
ES8	M{PyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mlz5TWM2OD1zLkeyOFE1KM7:TR?=	NVf1Z5Y{W0GQR1XS
NCI-H720	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4WwbWlEPTB;Mj6yNFY6QSEQvF2=	M1T3SXNCVkeHUh?=
EW-3	NUDnXJZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfzUGpKSzVyPUKuNlc2OzRizszN	NHTVVmZUSU6JRWK=
D-566MG	M3izUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jXcGlEPTB;Mj60OFU3QCEQvF2=	MXHTRW5ITVJ?
697	NFPGZoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTJwOESxO\|Mh\|ryP	M33BXnNCVkeHUh?=
ES5	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX71UpRrUUN3ME2yMlg5OTh7IN88US=>	MV\TRW5ITVJ?
COLO-684	NWLrSohQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3nDTGlEPTB;Mz61NVY6PiEQvF2=	NXvIZ\|JwW0GQR1XS
ML-2	M1PqXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLXS2xKUUN3ME2zMlYxODV6IN88US=>	MWrTRW5ITVJ?
MC-IXC	NEn5R2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmPUTWM2OD1\|Lk[zN\|k{KM7:TR?=	M13yZXNCVkeHUh?=
DB	MlTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTNwNkW0OFgh\|ryP	NHn6T3FUSU6JRWK=
HCC2218	MkXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fVV2lEPTB;Mz63N\|ExOyEQvF2=	MYfTRW5ITVJ?
NCI-H510A	NUO5TWJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGTnNmpKSzVyPUOuPFI4OjRizszN	NXzSfZhCW0GQR1XS
NCI-H526	NYfSPXJsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4fmNGlEPTB;Mz64Olk2QCEQvF2=	NXLtNoJQW0GQR1XS
MV-4-11	Mo\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3Je4tKSzVyPUSuNVM{OzRizszN	NWLZSJR2W0GQR1XS
PA-1	NVHpVlkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTRwMkWyPUDPxE1?	NVHWPWpzW0GQR1XS
EW-22	NIHDb5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTRwM{W4OkDPxE1?	M{f1fXNCVkeHUh?=
KASUMI-1	NX[0dGxXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4H3d2lEPTB;ND60NFExQSEQvF2=	NILteYVUSU6JRWK=
LU-139	NYLNbZc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYHB[XFLUUN3ME20Mlc2QDJ7IN88US=>	MWDTRW5ITVJ?
SBC-1	NHzp[W9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3j1SGlEPTB;ND64NFkxQCEQvF2=	NE[yd\|ZUSU6JRWK=
H4	NVzTTXU{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEnJU4NKSzVyPUSuPFk1PDNizszN	NXj6T4xYW0GQR1XS
EW-11	MmPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTVwMEiwO\|Ih\|ryP	NWq0NVdLW0GQR1XS
NBsusSR	NHnvXVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTVwMUKwOVUh\|ryP	MoTXV2FPT0WU
RPMI-8226	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTVwMUWyOFQh\|ryP	MmDxV2FPT0WU
DEL	M{LnTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;wTWM2OD13LkKwNFA3KM7:TR?=	NV:xdm84W0GQR1XS
ES4	NVe2XoY2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXrJR\|UxRTVwNUGzPFkh\|ryP	NWfCd3VpW0GQR1XS
GCT	MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PFXmlEPTB;NT61Olg2PiEQvF2=	MYjTRW5ITVJ?
NCI-H1048	M1PEdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTVwOUeyO\|Mh\|ryP	NHPLd\|ZUSU6JRWK=
NCI-SNU-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTZwMEKyJO69VQ>?	M2LmXnNCVkeHUh?=
ES7	NWjZOIdsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NECw[JhKSzVyPU[uNFM2PzdizszN	MXPTRW5ITVJ?
SW982	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTZwMEmxN\|ch\|ryP	NXTkdI4{W0GQR1XS
L-363	MoDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH3JSWtKSzVyPU[uN\|M6PzRizszN	NX;VRYlmW0GQR1XS
HT-1080	NHq2Z4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\kO\|JKSzVyPU[uOFk3QDNizszN	MnjrV2FPT0WU
HAL-01	NXXNXXgxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHXkWnFKSzVyPU[uOVExQSEQvF2=	MX;TRW5ITVJ?
NB14	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXy4W\|dKUUN3ME22MlY1ODN7IN88US=>	M4\ycHNCVkeHUh?=
EW-13	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3\JRWlEPTB;Nj63O\|QzPCEQvF2=	NV\0[VRyW0GQR1XS
NY	NGnVelBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVfPfWtsUUN3ME22Mlk1PjB3IN88US=>	MoXaV2FPT0WU
NCI-SNU-5	NESxb\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDafJBKSzVyPUeuNVA1OzNizszN	NEHNVJdUSU6JRWK=
MS-1	NIewO4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTdwMUe0PVQh\|ryP	M4\Z[3NCVkeHUh?=
EW-16	M{jLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUfGWGJjUUN3ME23MlMyQDZzIN88US=>	NYPCUVJVW0GQR1XS
LU-65	NHrSWWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYm0eJF7UUN3ME23MlQ5PDF5IN88US=>	NFXpUnZUSU6JRWK=
HGC-27	NGn6emxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTdwN{KxO\|Mh\|ryP	MonIV2FPT0WU
CTB-1	Mn\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGLHPXBKSzVyPUeuO\|YyPzVizszN	MWrTRW5ITVJ?
5637	MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlnmTWM2OD15LkmyPFYh\|ryP	NGO3dIdUSU6JRWK=
U251	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEftU\|FKSzVyPUeuPVQxOTZizszN	M{fn[3NCVkeHUh?=
HOS	NF2yT5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\MPYRKSzVyPUiuNlMxODdizszN	M2qxeXNCVkeHUh?=
DOHH-2	NIriUVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml\aTWM2OD16LkKzOVgh\|ryP	MnfnV2FPT0WU
EW-1	M{HkZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEjXT5BKSzVyPUiuN\|AxQDhizszN	NYXGfZRFW0GQR1XS
BV-173	M2Xle2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnPRTWM2OD16LkW1OVQh\|ryP	Ml\IV2FPT0WU
8-MG-BA	M4jUOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHyXXFGUUN3ME24MlY5QTh6IN88US=>	MVjTRW5ITVJ?
NB69	Mkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF3pPWFKSzVyPUiuO\|A6OjFizszN	MXzTRW5ITVJ?
NCI-H69	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTlwOUC5OlEh\|ryP	MWnTRW5ITVJ?
RS4-11	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTFzLkKyNFgh\|ryP	NHzTd5lUSU6JRWK=
ONS-76	M1rqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWjWU25PUUN3ME2xNU4zQTR5IN88US=>	NFK5VlZUSU6JRWK=
SF539	M3PjWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLmWJZKSzVyPUGxMlQ5QDlizszN	M1:5bHNCVkeHUh?=
HuO-3N1	NYnoVldWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFKxZ49KSzVyPUGxMlU4QTZizszN	M2PmV3NCVkeHUh?=
NCI-H1651	NGXnc29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLyTWM2OD1zMj6zNVE2KM7:TR?=	NEW4[HRUSU6JRWK=
KARPAS-45	M2HmfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTF{LkO3OkDPxE1?	M170XHNCVkeHUh?=
SK-NEP-1	M1P3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M12zb2lEPTB;MUKuOFYxQSEQvF2=	MnToV2FPT0WU
LAMA-84	Mk\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHzaOVdKSzVyPUGzMlExQTVizszN	NFjxSHdUSU6JRWK=
NCI-H1155	M1jx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTF\|LkK4OVYh\|ryP	Mor2V2FPT0WU
CTV-1	NYrWWnNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYLm[nlUUUN3ME2xN{41PDVizszN	Mo[wV2FPT0WU
QIMR-WIL	M2PrXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPQcFJKSzVyPUGzMlc5OTRizszN	M13WSHNCVkeHUh?=
H9	NIjrWXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTF\|Lki0O\|Uh\|ryP	MUfTRW5ITVJ?
SK-MEL-1	NI\4ZVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rYNWlEPTB;MUOuPVM1PyEQvF2=	NH2zTnNUSU6JRWK=
HD-MY-Z	MnLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTF2LkC2N\|ch\|ryP	NEfKPJZUSU6JRWK=
TI-73	NYiyVVI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTF2LkKzOVYh\|ryP	M2XGV3NCVkeHUh?=
JVM-3	NV;xNohCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVzob\|lZUUN3ME2xOU42PzF4IN88US=>	NVXQd5F4W0GQR1XS
D-247MG	Mnq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTF3LkW5N{DPxE1?	NYi2cXE3W0GQR1XS
VA-ES-BJ	M3fWTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\HSmRoUUN3ME2xOU43ODl5IN88US=>	MWPTRW5ITVJ?
NOS-1	MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoLPTWM2OD1zNT62OVIzKM7:TR?=	MYLTRW5ITVJ?
MOLT-4	NXHrTJlWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlPaTWM2OD1zNj63OVIh\|ryP	NF;JRYlUSU6JRWK=
Mo-T	NIjIT3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTF5LkC4OFkh\|ryP	NHqxbYdUSU6JRWK=
NCI-H1770	NIGwO\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MljVTWM2OD1zNz6xOVQ{KM7:TR?=	M1znXnNCVkeHUh?=
COLO-320-HSR	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTF5LkG4Nlch\|ryP	NIXuNHBUSU6JRWK=
TE-12	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTF5LkewOVQh\|ryP	MVHTRW5ITVJ?
NCI-H82	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXCSGdKSzVyPUG3Mlg4OjhizszN	MYrTRW5ITVJ?
NEC8	NVLEPWxWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1HxcmlEPTB;MUiuNVMyPiEQvF2=	MXjTRW5ITVJ?
HSC-3	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rTSGlEPTB;MUiuO\|QyPCEQvF2=	MVPTRW5ITVJ?
NCI-H1092	MkXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE[0XWRKSzVyPUG4Mlc2QTVizszN	M1rTfHNCVkeHUh?=
NCI-H292	NWDPRYRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH32WYxKSzVyPUG5MlA1QDlizszN	MXPTRW5ITVJ?
L-428	NGHRdGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{TPRWlEPTB;MUmuOVU6KM7:TR?=	NGi0dnVUSU6JRWK=
LU-134-A	NYXkSoo3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkWxTWM2OD1zOT61O\|Ih\|ryP	NEj4bFRUSU6JRWK=
GI-ME-N	NXryRYQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTF7LkW3OFch\|ryP	MU\TRW5ITVJ?
ALL-PO	MmP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXXaVIVGUUN3ME2xPU42QTd{IN88US=>	MYHTRW5ITVJ?
D-283MED	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;LWnpKSzVyPUG5MlkyPSEQvF2=	NHfOUVhUSU6JRWK=
D-423MG	M1foemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFj2d4hKSzVyPUG5Mlk6PjdizszN	NWnaV3MzW0GQR1XS
CAKI-1	NU\jdWRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoP5TWM2OD1{MD6yNlE6KM7:TR?=	NHnyZ4hUSU6JRWK=
ETK-1	MojGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mof5TWM2OD1{MD6yOlE2KM7:TR?=	NUXj[2MzW0GQR1XS
G-402	M1XhN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXjjSWxlUUN3ME2yNE42OzN2IN88US=>	NHHzV4VUSU6JRWK=
HL-60	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mkf2TWM2OD1{MT6xOlE{KM7:TR?=	MUfTRW5ITVJ?
A2058	NVnxNFZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MknLTWM2OD1{MT60OFc4KM7:TR?=	MVXTRW5ITVJ?
CHP-212	MnnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPMRVhlUUN3ME2yNU46ODVzIN88US=>	MX;TRW5ITVJ?
KY821	M4PUPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3TkUmlEPTB;MkGuPVc2KM7:TR?=	NWnrcXZmW0GQR1XS
TYK-nu	NWTv[oI2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXPOnc1UUN3ME2yNk4xPjVzIN88US=>	MXzTRW5ITVJ?
JVM-2	NG\ST5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWfwW3hsUUN3ME2yNk4zQTh\|IN88US=>	NFnSVI5USU6JRWK=
KU812	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXvPbW1IUUN3ME2yNk44OzF{IN88US=>	MX7TRW5ITVJ?
MKN28	NVjjUVI1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn22TWM2OD1{Mj65NFE2KM7:TR?=	MUDTRW5ITVJ?
ECC10	NFPzWVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoPBTWM2OD1{Mz63OFEh\|ryP	M2HBTHNCVkeHUh?=
BHT-101	NWXWfWo5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTJ2LkCwNFgh\|ryP	NGf1XW9USU6JRWK=
DU-4475	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTJ2LkOzN\|ch\|ryP	MUjTRW5ITVJ?
769-P	NEDGPHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3vDRWlEPTB;MkSuPFQ3PiEQvF2=	NXfESXdmW0GQR1XS
HEC-1	NI\MUpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVHJR\|UxRTJ3LkS0OUDPxE1?	MWnTRW5ITVJ?
MOLT-13	MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTJ3LkWzN\|Eh\|ryP	Mmn1V2FPT0WU
8505C	NEXmXo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mly3TWM2OD1{Nj60PVc4KM7:TR?=	NHfhNZpUSU6JRWK=
GB-1	NUKyUVQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTJ4LkexO\|Yh\|ryP	NFrWPG1USU6JRWK=
SF126	NVnTU29YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnNU5RYUUN3ME2yOk44PjR6IN88US=>	MkXsV2FPT0WU
A4-Fuk	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPxZmhKSzVyPUK3MlEzPzFizszN	MoXYV2FPT0WU
OVCAR-8	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUTlZoptUUN3ME2yO{4yPTN7IN88US=>	M1z1NnNCVkeHUh?=
NCI-H1304	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmrYTWM2OD1{Nz61OEDPxE1?	MlzlV2FPT0WU
GR-ST	Mlr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHXJNohKSzVyPUK4MlA1PyEQvF2=	NEPmN29USU6JRWK=
G-401	MlPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlrGTWM2OD1{OD61NFk3KM7:TR?=	M1zqd3NCVkeHUh?=
LXF-289	NFXiNY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1PDNGlEPTB;MkiuOVY2OSEQvF2=	NXqydXllW0GQR1XS
DBTRG-05MG	M4riOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWr5bG5pUUN3ME2yPE46OjB2IN88US=>	M2TjNHNCVkeHUh?=
YKG-1	MkDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmq2TWM2OD1{OT64Olgh\|ryP	MYPTRW5ITVJ?
GAMG	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTJ7Lkm5N{DPxE1?	NELodFhUSU6JRWK=
HCT-116	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MULJR\|UxRTNyLkC1OFgh\|ryP	NGfuS4FUSU6JRWK=
S-117	NH7tPXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTQeYhjUUN3ME2zNU4zOjV5IN88US=>	MkLMV2FPT0WU
NCI-H1693	NWTxR3lbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3aTWM2OD1\|Mz62OVQzKM7:TR?=	NW\0ZYw1W0GQR1XS
A427	M1iyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTN\|Lkm5O\|Yh\|ryP	M2C5bXNCVkeHUh?=
HT-29	NYnVZXVbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTN2Lk[wN\|Ih\|ryP	NGTPfmRUSU6JRWK=
P12-ICHIKAWA	NFzXW2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTN2Lke0PVEh\|ryP	MYDTRW5ITVJ?
CAL-51	NXnrXIRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTN3LkC3NFkh\|ryP	M3rV[3NCVkeHUh?=
Ramos-2G6-4C10	NEHmbGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIHKTodKSzVyPUO1MlI1OjVizszN	NHi1dIJUSU6JRWK=
SCH	MkXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYHEWI16UUN3ME2zOk41OTd2IN88US=>	NHHUV4RUSU6JRWK=
SK-MEL-24	NHjZcXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mny0TWM2OD1\|Nj65NFQ1KM7:TR?=	M3joeXNCVkeHUh?=
SW1573	NXi5VIJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHJW2RKSzVyPUO4MlczOTZizszN	MV3TRW5ITVJ?
BALL-1	Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTN7LkKxNlkh\|ryP	NEfVXYNUSU6JRWK=
BE-13	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo\5TWM2OD1\|OT6zNlkh\|ryP	M4jPVHNCVkeHUh?=
GI-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDxd4hCUUN3ME2zPU45PjR5IN88US=>	Mk\UV2FPT0WU
GOTO	NXLYWJVzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGrmcoNKSzVyPUO5MlkyOzlizszN	MU\TRW5ITVJ?
A673	MofwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnsO\|U4UUN3ME20NU4xOzR\|IN88US=>	NXTIW4V1W0GQR1XS
KG-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17VeGlEPTB;NEOuN\|k1KM7:TR?=	NGm3c2dUSU6JRWK=
GP5d	NIXWUFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MY\JR\|UxRTR2LkC2OlYh\|ryP	M2fGeHNCVkeHUh?=
MFM-223	MlrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjkNo1KSzVyPUS0MlEzOjhizszN	MmXmV2FPT0WU
OAW-42	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTR2LkK2OFMh\|ryP	MnTyV2FPT0WU
C8166	NXnENnFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWfJR\|UxRTR3LkC4NlIh\|ryP	MWDTRW5ITVJ?
LU-99A	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HZNWlEPTB;NE[uNVMzOiEQvF2=	NHrrZYdUSU6JRWK=
NCI-H23	NEDQNJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTR4LkG3PFUh\|ryP	M2PUUnNCVkeHUh?=
HO-1-N-1	MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDOVplKSzVyPUS3MlA6QThizszN	M1HvPHNCVkeHUh?=
A3-KAW	NUXsWHVlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1\5O2lEPTB;NEeuNVAxPyEQvF2=	NVjIV4lGW0GQR1XS
CGTH-W-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|UxRTR5LkWwOlkh\|ryP	NHG2cFFUSU6JRWK=
DJM-1	M{f0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1LXb2lEPTB;NEeuOVQyOyEQvF2=	M4DYb3NCVkeHUh?=
A101D	Mlj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1LlUGlEPTB;NEeuOlM2PyEQvF2=	MULTRW5ITVJ?
BB30-HNC	MnrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{mybmlEPTB;NEiuN\|A4OiEQvF2=	M1K3RXNCVkeHUh?=
T98G	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmPTTWM2OD12OD60OlM{KM7:TR?=	Ml3YV2FPT0WU
NCI-H1573	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1ixS2lEPTB;NEmuOFQ3OiEQvF2=	NXGy[Xh4W0GQR1XS
MEG-01	NIXxOoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHjMTnlKSzVyPUS5Mlc1OTFizszN	NELEUXFUSU6JRWK=
WM-115	NXjieVRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVK1O5NYUUN3ME20PU46OjJ{IN88US=>	MYPTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western Blot	DR5/CHOP; PubMed: 25531448 PLoS One (A) U87 GBM cells were treated with Olaparib (10 µM) for the indicated time points, subjected to immunoblotting and analyzed for the expression of DR5. B-D) U87 (B), U373 (C) and LN229 GBM cells (D) were treated with increasing concentrations of Olaparib (µM) for 7 hours, subjected to immunoblotting and analyzed for the expression of CHOP and DR5. E–F) MDA-MB-468 (E) and MDA-MB-436 (F) were treated with increasing concentrations (µM) of Olaparib for 7 hours, harvested for immunoblotting and analyzed for the expression of DR5. γH2AX/H2AX; PubMed: 22933245 EMBO Mol Med FK866 exacerbates levels of γH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and γH2AX. pATM; PubMed: 27686740 Cell cycle (C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. 53BP1; PubMed: 27686740 Cell cycle (C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. NF-kB; PubMed: 27686740 Cell cycle (C) Western blot analysis in HN9-cisR cells according to changes in olaparib doses. Olaparib induced pATM and 53BP1 activation in a dose-dependent manner in HN9-cisR cells. pS6/S6; PubMed: 24831086 Oncotarget HCC1937 cells (BRCA1-inactive) were treated with 10 nM olaparib with indicated times. Whole-cell lysates were prepared and analyzed by Western blotting with the indicated antibodies.	25531448 22933245 27686740 24831086
Immunofluorescence	DNA damage; PubMed: 27686740 Cell Cycle (A) A comet assay and (B) γH2AX immunofluorescence assay were performed 72 h after olaparib treatment to identify DNA damage. A relatively higher level of DNA damage was observed in HN9-cisR cells; however, olaparib also induced slight DNA damage in olaparib-resistant HN4-cisR cells. Magnification: × 100 (comet assay); × 400 (γH2AX). γH2AX; PubMed: 28069876 Mol Cancer Ther Representative images of immunofluorescence (IF) staining for γH2AX in 22RV1 cells treated with of BI2536 (5 nM), Olaparib (10 µM) or both for 24 h. 22RV1 cells (1 × 105) were plated in 6-well plates on day 0 and then treated with BI2536, Olaparib or both for 24 h.	27686740 28069876
Growth inhibition assay	Cell viability ; PubMed: 25531448 PLoS One A-D): U87 (A), U373 (B), LN229 (C) and MDA-MB-468 (D) cells were treated with suboptimal dosages of TRAIL (A: 100 ng/ml, B: 25 ng/ml, C: TRAIL 200 ng/ml, D: 10 ng/ml), Olaparib (A–C: 10 µM, D: 5 µM) or the combination of both reagents for 48 hours. Thereafter, MTT assays were performed to determine cellular viability.	25531448
ELISA	IL-8; PubMed: 28456021 Virology ELISA measuring PAR levels in Akata-EBV cells. Cells were treated with 2.5 μM olaparib for 24 h to inhibit PARP activity. Data are shown as pg of PAR per μg of protein. GLP-1; PubMed: 29392078 Aging Dis Olaparib enhances promotes GLP-1 secretion in NCI-H716 cells Cells were stimulated for 30 minutes with or without 16 mM glucose. GLP-1 was measured by ELISA. Bars represent the mean of three independent experiments normalized to the control. Error bars indicate standard deviation. Statistical analyses were performed by two-tailed Student’s t-test and significance is denoted by asterisks where *P<0.05.	28456021 29392078

In vivo

Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. ^[1] Olaparib shows great response to Brca1^-/-;p53^-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad^-/-;p53^-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. ^[3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. ^[4]

Protocol

Kinase Assay: ^[1]	- Collapse FlashPlate assay (96-well screening assay): To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl₂,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD⁺ final assay concentration, and 0.075 μCi ³H-NAD⁺ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
Cell Research: ^[1]	- Collapse Cell lines: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D Concentrations: 1-300 nM Incubation Time: 7-14 days Method: The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50. (Only for Reference)
Animal Research: ^[3]	- Collapse Animal Models: Brca1^-/-;p53^-/- mammary tumors are generated in K14cre;Brca1^F/F;p53^F/F mice. Dosages: 50 mg/kg Administration: Administered via i.p. injection at 10 μL/g of body weight (Only for Reference)

References

[4] Weston VJ, et al, Blood, 2010, 116(22), 4578-4587.

- Collapse

Solubility (25°C)

In vitro	DMSO	86 mg/mL warmed (197.94 mM)
	Water	0.002 mg/mL (0.0 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Olaparib (AZD2281) SDF

Molecular Weight	434.46
Formula	C₂₄H₂₃FN₄O₃
CAS No.	763113-22-0
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Ku-0059436
Smiles	C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04515836	Not yet recruiting	Drug: Olaparib	Mesothelioma\|Homologous Recombination Deficiency	University of Chicago\|AstraZeneca	October 15 2020	Phase 2
NCT04024254	Recruiting	Drug: Folic Acid Tablet	Ovarian Cancer\|Breast Cancer\|Folic Acid Deficiency	Rush University Medical Center	July 21 2020	Phase 2\|Phase 3
NCT04298021	Recruiting	Drug: AZD6738\|Drug: Durvalumab\|Drug: Olaparib	Bile Duct Cancer\|Chemotherapy Effect	Seoul National University Hospital	June 25 2020	Phase 2
NCT04330040	Recruiting	Drug: Olaparib	Ovarian Cancer\|Breast Cancer	AstraZeneca	May 30 2020	Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to prepare the solution of the compound (S1060) for in vivo study?
Answer:
We recommend the following formulation: 4% DMSO+30% PEG300+ 66%H2O. It is a clear solution and can be used for IP injection.
Question 2:
I saw that the solubility of the compound for in vivo on the website had been changed, why the change has been made?
Answer:
For the formulation for in vivo, the compound dissolving in 15% Captisol (former solubility) is a suspension, and it is fine for oral gavage. And now, dissolving in 4% DMSO+30% PEG 300+ddH2O is a clear solution, and is for injection.
Question 3:
How long can the chemical compound be stable in DMEM at 4 °C?
Answer:
The compound is stable in DMEM at 4 degree for one week.

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Selective PARP Inhibitors

AG-14361 : PARP1-selective, K_i<5 nM.
Selective PARP Inhibitors

UPF 1069 : PARP2-selective, IC50=0.3 μM.
Most Potent PARP Inhibitor

MK-4827 (Niraparib) : PARP1, IC50=3.8 nM; PARP2, IC50=2.1 nM.
PARP Inhibitor in Clinical Trial

Iniparib (BSI-201) : Phase III for solid tumors.
Newest PARP Inhibitor

BMN 673 : Novel PARP inhibitor with IC50 of 0.58 nM. Also a potent inhibitor of PARP-2, but does not inhibit PARG and highly sensitive to PTEN mutation.

Related PARP Products

G007-LK ^New

G007-LK is a potent and selective tankyrase inhibitor with IC50 of 46 nM and 25 nM for TNKS1/2, respectively.
NU1025 ^New

NU1025 (NSC 696807) is a potent PARP inhibitor with IC50 of 400 nM.
SCR7 ^New

SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ). It increases the efficiency of HDR-mediated genome editing up to 19-fold using CRISPR/Cas9 in mammalian cells and mouse embryos.
Veliparib (ABT-888)

Veliparib (ABT-888, NSC 737664) is a potent inhibitor of PARP1 and PARP2 with K_i of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Veliparib increases autophagy and apoptosis. Phase 3.

Features:Increases the efficacy of common cancer therapies such as radiation and alkylating agents.
Rucaparib (AG-014699) phosphate

Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with K_i of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.

Features:The first PARP inhibitor used in clinical trials combined with temozolomide.
Talazoparib (BMN 673)

Talazoparib (BMN 673, LT-673) is a novel PARP inhibitor with IC50 of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.

Features:Most potent and selective PARPi reported thus far.
Iniparib (BSI-201)

Iniparib (BSI-201, NSC-746045, IND-71677) is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC). Phase 3.
PJ34 HCl

PJ34 HCl is the hydrochloride salt of PJ34, which is a PARP inhibitor with EC50 of 20 nM and is equally potent to PARP1/2.

Features:Water-soluble PARP1/2 inhibitor with >10,000-fold potentcy vs. 3-aminobenzamide (prototypical PARP inhibitor). Potential uses in cardiovascular diseases (stroke, cerebral ischemia, & myocardial ischemia).
AG-14361

AG14361 is a potent inhibitor of PARP1 with K_i of <5 nM in a cell-free assay. It is at least 1000-fold more potent than the benzamides.

Features:The 1st high-potency PARP-1 inhibitor with the specificity & in vivo activity to enhance chemotherapy and radiation therapy of human cancers.
A-966492

A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with K_i of 1 nM and 1.5 nM, respectively.

Features:A promising, structurally diverse benzimidazole analogue that is being further characterized preclinically.

Choose Your Country or Region

By Signaling Pathways

By product type

Olaparib (AZD2281)